(Q36589874)

15 August 2017

1 reference

title

Future directions for vaccine-based therapies (English)

1 reference

15 August 2017

Johannes Vieweg

1

1 reference

15 August 2017

publication date

1 September 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

24

1 reference

15 August 2017

issue

5

1 reference

15 August 2017

page(s)

448-455

1 reference

The dendritic cell system and its role in immunogenicity

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Deficient cellular immunity--finding and fixing the defects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Technology Insight: vaccine therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Cancer immunotherapy: moving beyond current vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Costimulatory wars: the tumor menace

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Negative regulation of T-cell function by PD-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Derangement of immune responses by myeloid suppressor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

L-arginine metabolism in myeloid cells controls T-lymphocyte functions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Certified professionals: CD4(+)CD25(+) suppressor T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Control of T-cell activation by CD4+ CD25+ suppressor T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Natural selection of tumor variants in the generation of "tumor escape" phenotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

A survey of telomerase activity in human cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

True immunogenicity of oncofetal antigen/immature laminin receptor protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Expression and immunogenicity of oncofetal antigen-immature laminin receptor in human renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Synergy between tumor immunotherapy and antiangiogenic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Angiogenesis in cancer, vascular, rheumatoid and other disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Matrix metalloproteinases: biologic activity and clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

What's new in the treatment of advanced prostate cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

A new era for cancer immunotherapy based on the genes that encode cancer antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

The role of CD4+ T cell responses in antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

The central role of CD4(+) T cells in the antitumor immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Engagement of the OX-40 receptor in vivo enhances antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

The antigen dose determines T helper subset development by regulation of CD40 ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Cytokine induction by the immunomodulators imiquimod and S-27609

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Imiquimod, a topical immune response modifier, induces migration of Langerhans cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Antigenic targets for renal cell carcinoma immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

The molecular program induced in T cells undergoing homeostatic proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

Cancer immunotherapy: breaking the barriers to harvest the crop

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.012

10.1016/J.UROLONC.2005.08.012

7 January 2021

Identifiers

DOI

1 reference

15 August 2017

1 reference